5 results about "Malignancy" patented technology

Antibodies which specifically bind to components of the DNA synthesome which are altered in malignant cells are disclosed. These antibodies can be used, inter alia, to diagnose, prognoses, and treat malignancy and in assays to screen cells, tissues, and body fluids for the presence of a malignant phenotype. These antibodies can be further used to identify test compounds having the ability to suppress the malignant phenotype in a cell by assaying for the ability to inhibit or block the function of an altered component of the DNA synthesome associated with the malignant phenotype. Further, disclosed herein are methods and kit for minimally invasively detecting the presence of neoplasms and malignant conditions using easily obtainable body fluids, such as blood, plasma, lymph, pleural fluid, spinal fluid, saliva, sputum, urine, and semen, for example, to both detect the presence of cancer as well as assess the stage of the disease and the prognosis of the patient. By detecting the presence of an altered form of a component of the DNA synthesome in body fluid, one can diagnose and prognose malignancy. The disclosed method and kit therefor can be used as a diagnostic biomarker for malignancy as well as a means of monitoring the progress and effectiveness of therapeutics.

Provided are T cell receptors (TCR) and TCR variable regions that can selectively bind the T-cell leukemia/lymphoma 1 (TCL1) oncoprotein. The TCR may be utilized in various therapies, such as autologous TCL1-TCR adoptive T cell therapy, to treat a cancer, such as a B-cell malignancy or a solid tumor expressing TCL1. Methods for expanding a population of T cells that target TCL1 are also provided.

Compositions and methods for transient immunodepletion of specific subsets of a subject's immune cells are disclosed. The methods generally include administering to the subject an effective amount of a radiolabeled antibody against CD19, CD20, CD33, CD38, CD45RA, CD52, or a combination thereof. The effective amount of the radiolabeled antibody depletes at least 50% of the targeted immune cells, and less than 20% of the subject's stem cells. When used alone, these methods may target lymphomas, leukemias, and myelomas, and/or may additionally allow repopulation of non-autoreactive immune cells in patients with an autoimmune disease. When these methods precede certain cell-based therapies, such as adoptive cell therapy and/or hematopoietic stem cell therapy, the methods are able to enhance the outcome of the cell-based therapies while minimizing adverse effects.